CLINICAL ANALYSIS OF HIGH-GRADE B-CELL LYMPHOMA IN 27 YOUNG AND MIDDLE-AGED PATIENTS

Abstract

Objective To analyze the clinical features, therapeutic effects, and prognosis of high-grade B-cell lymphoma (HGBL) in young and middle-aged patients. Methods The clinical data of 27 young and middle-aged patients with HGBL were analyzed retrospectively. Results In 27 young and middle-aged patients with HGBL, advanced Ann Arbor stage, high age-adjusted international prognostic index score, many extranodal organ involvement, and bone marrow involvement were more common in patients with double/triple-hit lymphoma (HGBL-DT) compared with patients with HGBL, not otherwise specified (HGBL-NOS) (P<0.05). In the short-term efficacy comparison, the overall response rate of patients with HGBL-NOS was significantly higher than that of patients with HGBL-DT (P<0.05). In the long-term efficacy comparison, the progression free survival and overall survival of patients with HGBL-NOS were both significantly superior to those of patients with HGBL-DT (P<0.05). In 6 patients with early HGBL-NOS, remission was achieved in both 3 patients treated with the R-CHOP/EPOCH regimen and 3 patients treated with the high-intensity chemotherapy regimen. In 9 patients with advanced HGBL-NOS, 5 of 8 patients treated with the R-CHOP/EPOCH regimen achieved remission, and 1 patient who was treated with the high-intensity chemotherapy regimen achieved remission. Conclusion HGBL-DT is more aggressive than HGBL-NOS in young and middle-aged patients, with worse prognosis. The high-intensity chemotherapy regimen may be considered for patients with HGBL-DT.

Keywords

• lymphoma, b-cell|chemotherapy, cancer, regional perfusion|progression-free survival|comparative effectiveness research|prognosis